MCID: ALC004
MIFTS: 69

Alcohol Abuse

Categories: Genetic diseases, Mental diseases, Metabolic diseases, Rare diseases, Skin diseases, Smell/Taste diseases

Aliases & Classifications for Alcohol Abuse

Summaries for Alcohol Abuse

Genetics Home Reference : 25 Alcohol use disorder is a diagnosis made when an individual has severe problems related to drinking alcohol. Alcohol use disorder can cause major health, social, and economic problems, and can endanger affected individuals and others through behaviors prompted by impaired decision-making and lowered inhibitions, such as aggression, unprotected sex, or driving while intoxicated.

MalaCards based summary : Alcohol Abuse, also known as alcohol use disorder, is related to alcohol-induced mental disorder and nonalcoholic steatohepatitis, and has symptoms including hangover from any alcohol or other drugs substance and hangover from alcohol. An important gene associated with Alcohol Abuse is CYP2E1 (Cytochrome P450 Family 2 Subfamily E Member 1), and among its related pathways/superpathways are Beta-Adrenergic Signaling and GABAergic synapse. The drugs Dopamine and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and liver, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A substance abuse that involves the recurring use of alcoholic beverages despite negative consequences.

Wikipedia : 76 Alcohol abuse (also called alcohol dependence, alcohol misuse, alcohol addiction, or alcoholism)... more...

Related Diseases for Alcohol Abuse

Diseases in the Alcohol Abuse family:

Alcohol Sensitivity, Acute

Diseases related to Alcohol Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1207)
# Related Disease Score Top Affiliating Genes
1 alcohol-induced mental disorder 33.6 DRD2 SLC6A4
2 nonalcoholic steatohepatitis 33.3 CYP2E1 GPT SLC17A5
3 methanol poisoning 31.1 AKR1A1 CYP2E1
4 migraine with or without aura 1 30.7 CNR1 DRD1 DRD2 DRD3 DRD4 SLC6A4
5 anxiety 30.4 BDNF CNR1 SLC6A4
6 liver disease 30.4 ABCB7 CYP2E1 GGT1 GPT SLC17A5 TF
7 viral hepatitis 30.3 ABCB7 GGT1 GPT SLC17A5
8 opiate dependence 30.2 DRD2 DRD3 SLC6A4
9 tobacco addiction 30.2 ALDH2 ANKK1 DRD2 SLC6A4
10 conduct disorder 30.2 ALDH2 DRD2 DRD4 SLC6A4
11 post-traumatic stress disorder 30.0 BDNF CNR1 DRD2 FAAH SLC6A4
12 liver cirrhosis 30.0 ALDH2 CYP2E1 GGT1 GPT SLC17A5 TF
13 alcoholic liver cirrhosis 30.0 ALDH2 CYP2E1 SLC17A5 TF
14 eating disorder 29.9 BDNF CNR1 DRD2 SLC6A4
15 alcoholic hepatitis 29.9 CYP2E1 GPT SLC17A5
16 major depressive disorder 29.9 BDNF DRD2 DRD3 DRD4 PRL SLC6A4
17 cannabis abuse 29.9 BDNF CNR1
18 bilirubin metabolic disorder 29.8 GGT1 GPT SLC17A5
19 obstructive jaundice 29.8 GGT1 GPT SLC17A5
20 pyridoxine deficiency 29.8 GPT SLC17A5
21 delusional disorder 29.8 DRD2 DRD3 DRD4
22 autism 29.8 BDNF DRD2 DRD3 DRD4 SLC6A4
23 cocaine dependence 29.8 DRD2 DRD3 SLC6A4
24 drug dependence 29.8 ANKK1 BDNF CNR1 DRD2 DRD3 SLC6A4
25 gilles de la tourette syndrome 29.8 BDNF DRD2 DRD4
26 alexithymia 29.8 ANKK1 DRD2 SLC6A4
27 fetal alcohol spectrum disorder 29.8 AKR1A1 ALDH9A1 BDNF
28 mood disorder 29.8 BDNF DRD2 DRD3 DRD4 SLC6A4
29 pathological gambling 29.8 DRD1 DRD2 DRD3 DRD4 SLC6A4
30 cocaine abuse 29.7 DRD2 PRL SLC6A4
31 polysubstance abuse 29.7 CNR1 DRD2 DRD3 FAAH
32 body mass index quantitative trait locus 11 29.7 CNR1 CYP2E1 DRD2 FAAH GGT1 GPT
33 heroin dependence 29.7 ANKK1 BDNF DRD2 DRD4
34 oppositional defiant disorder 29.7 DRD2 DRD4 SLC6A4
35 generalized anxiety disorder 29.7 BDNF DRD2 SLC6A4
36 antisocial personality disorder 29.6 ALDH2 ANKK1 DRD2 SLC6A4
37 schizophrenia 29.6 BDNF CNR1 DRD1 DRD2 DRD3 DRD4
38 social phobia 29.6 DRD2 PRL SLC6A4
39 anorexia nervosa 29.6 BDNF PRL SLC6A4
40 disease of mental health 29.6 BDNF CNR1 DRD2 DRD3 DRD4 SLC6A4
41 postpartum depression 29.5 BDNF PRL SLC6A4
42 fatty liver disease 29.5 CYP2E1 GGT1 SLC17A5
43 bipolar i disorder 29.5 BDNF DRD1 SLC6A4
44 paraquat poisoning 29.5 GPT SLC17A5
45 personality disorder 29.5 ALDH2 ANKK1 BDNF DRD2 DRD4 PRL
46 kwashiorkor 29.4 GPT SLC17A5 TF
47 substance dependence 29.3 BDNF CNR1 DRD2 DRD3 DRD4 SLC6A4
48 bipolar disorder 29.3 BDNF DRD1 DRD2 DRD3 DRD4 GGT1
49 schizoaffective disorder 29.3 BDNF DRD2 DRD3 PRL SLC6A4
50 attention deficit-hyperactivity disorder 29.2 ANKK1 BDNF DRD1 DRD2 DRD3 DRD4

Comorbidity relations with Alcohol Abuse via Phenotypic Disease Network (PDN): (show all 20)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Alcoholic Cardiomyopathy
Alcoholic Gastritis Alcoholic Hepatitis
Alcoholic Liver Cirrhosis Alcoholic Neuropathy
Alcohol-Induced Mental Disorder Cocaine Abuse
Deficiency Anemia Familial Atrial Fibrillation
Fatty Liver Disease Hepatic Encephalopathy
Hypertension, Essential Major Depressive Disorder
Pancreatitis, Hereditary Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder

Graphical network of the top 20 diseases related to Alcohol Abuse:



Diseases related to Alcohol Abuse

Symptoms & Phenotypes for Alcohol Abuse

UMLS symptoms related to Alcohol Abuse:


hangover from any alcohol or other drugs substance, hangover from alcohol

GenomeRNAi Phenotypes related to Alcohol Abuse according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.33 ANKK1
2 Decreased viability GR00221-A-1 10.33 GABRA2
3 Decreased viability GR00221-A-2 10.33 ANKK1 GABRA2
4 Decreased viability GR00221-A-4 10.33 ANKK1 GABRA2
5 Decreased viability GR00240-S-1 10.33 ABCB7
6 Decreased viability GR00381-A-1 10.33 GGT1 SLC6A4
7 Decreased viability GR00381-A-3 10.33 SLC6A4
8 Decreased viability GR00402-S-2 10.33 ABCB7 AKR1A1 ALDH2 ALDH9A1 ANKK1 BDNF
9 no effect GR00402-S-1 9.96 ABCB7 AKR1A1 ALDH2 ALDH9A1 ANKK1 BDNF
10 Decreased shRNA abundance GR00251-A-1 9.91 ALDH9A1 CYP2E1
11 Decreased shRNA abundance GR00251-A-2 9.91 ALDH9A1 CYP2E1
12 Decreased shRNA abundance GR00297-A 9.91 ABCB7 AKR1A1 ALDH9A1 CYP2E1 GABRA2
13 shRNA abundance <= 50% GR00343-S 9.32 AKR1A1 ALDH2 ANKK1 DRD1 DRD2 DRD3

MGI Mouse Phenotypes related to Alcohol Abuse:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 ALDH2 BDNF CNR1 CYP2E1 DRD1 DRD2
2 homeostasis/metabolism MP:0005376 10.19 ABCB7 AKR1A1 ALDH2 BDNF CNR1 CYP2E1
3 growth/size/body region MP:0005378 10.1 ABCB7 AKR1A1 ALDH2 BDNF CNR1 DRD1
4 integument MP:0010771 9.9 ALDH2 ALDH9A1 BDNF CNR1 DRD1 DRD2
5 mortality/aging MP:0010768 9.83 ABCB7 AKR1A1 ALDH2 BDNF CNR1 CYP2E1
6 nervous system MP:0003631 9.44 ABCB7 ALDH2 BDNF CNR1 DRD1 DRD2

Drugs & Therapeutics for Alcohol Abuse

Drugs for Alcohol Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 391)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
2
Bupropion Approved Phase 4,Phase 2,Phase 1,Not Applicable 34841-39-9, 34911-55-2 444
3
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
4
Fluoxetine Approved, Vet_approved Phase 4,Phase 2 54910-89-3 3386
5
Acamprosate Approved, Investigational Phase 4,Phase 3,Phase 2 77337-76-9 71158
6
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 56-12-2 119
7
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 60142-96-3 3446
8 Nefopam Approved, Investigational Phase 4 13669-70-0
9
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
10
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
11
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
12
Clonidine Approved Phase 4,Early Phase 1 4205-90-7 2803
13
Acetaminophen Approved Phase 4,Not Applicable 103-90-2 1983
14
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 16590-41-3 5360515
15
Topiramate Approved Phase 4,Phase 2,Phase 3,Not Applicable 97240-79-4 5284627
16
Ondansetron Approved Phase 4,Phase 2,Phase 3,Phase 1 99614-02-5 4595
17
Citalopram Approved Phase 4,Phase 2,Not Applicable 59729-33-8 2771
18
Chlorzoxazone Approved Phase 4,Not Applicable 95-25-0 2733
19
Methylphenidate Approved, Investigational Phase 4,Phase 1,Early Phase 1 113-45-1 4158
20
Varenicline Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 249296-44-4 5310966
21
Dutasteride Approved, Investigational Phase 4,Not Applicable 164656-23-9 6918296 152945
22
Zonisamide Approved, Investigational Phase 4,Phase 3,Phase 2 68291-97-4 5734
23 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
25
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
26
Haloperidol Approved Phase 4 52-86-8 3559
27
Lorazepam Approved Phase 4,Phase 2 846-49-1 3958
28
Ribavirin Approved Phase 4,Phase 2 36791-04-5 37542
29
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
30
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
31
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
32
Disulfiram Approved Phase 4,Phase 2 97-77-8 3117
33
Sertraline Approved Phase 4,Phase 2,Phase 1 79617-96-2 68617
34
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54-11-5 942 89594
35
Methadone Approved Phase 4,Phase 2 76-99-3 4095
36
Naloxone Approved, Vet_approved Phase 4,Phase 3 465-65-6 5284596
37
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 52485-79-7 40400 644073
38
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
39
Cocaine Approved, Illicit Phase 4,Phase 2,Phase 1 50-36-2 5760 446220
40
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-56-6 439302 53477758
41
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2 132539-06-1 4585
42
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
43
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
44
Clozapine Approved Phase 4 5786-21-0 2818
45
Choline Approved, Nutraceutical Phase 4,Phase 1,Phase 2,Not Applicable 62-49-7 305
46
Glutamic Acid Approved, Nutraceutical Phase 4,Phase 2 56-86-0 33032
47
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Not Applicable 59-30-3 6037
48
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
49
Heroin Illicit, Investigational Phase 4 561-27-3 5462328
50 Anti-Infective Agents, Local Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 825)
# Name Status NCT ID Phase Drugs
1 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
2 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE) Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
3 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
4 Epidural Analgesia for Pancreatitis (Epipan Study) Unknown status NCT02126332 Phase 4
5 Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse Completed NCT00190957 Phase 4 Atomoxetine;placebo
6 Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence Completed NCT00223249 Phase 4 Quetiapine
7 Naltrexone Treatment of Alcohol Abuse in Schizophrenia Completed NCT00145847 Phase 4 Naltrexone or Placebo
8 Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism Completed NCT00452543 Phase 4 acamprosate;escitalopram;Placebo
9 Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake Completed NCT01342341 Phase 4 Parafon Forte
10 Adolescent Family-Based Alcohol Prevention Completed NCT00858065 Phase 4
11 Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults Completed NCT00550394 Phase 4 quetiapine and placebo;Quetiapine and Topiramate
12 Treatment of Patients With Alcoholism and Attention Deficit Disorder Completed NCT00261872 Phase 4 Methylphenidate
13 Bupropion as a Smoking Cessation Aid in Alcoholics Completed NCT00044434 Phase 4 bupropion (Wellbutrin)
14 Varenicline in Drug Treatment Completed NCT01286584 Phase 4 varenicline;placebo
15 Dutasteride Treatment for the Reduction of Heavy Drinking in Men Completed NCT01758523 Phase 4 Dutasteride;sugar pill
16 Dutasteride for the Reduction of Alcohol Use in Male Drinkers Completed NCT01262287 Phase 4 Dutasteride;Placebo
17 Zonisamide vs. Placebo in the Treatment of Alcohol Dependence Completed NCT00595556 Phase 4 zonisamide;Placebo
18 Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy Completed NCT01087736 Phase 4 Topiramate
19 Citicoline for Alcohol Dependence Completed NCT02074735 Phase 4 Placebo;Citicoline
20 AID-trial Assertive Intervention After Deliberate Self-harm Completed NCT00700089 Phase 4
21 Naltrexone for Bipolar Disorder and Alcohol Dependence Completed NCT00223275 Phase 4 Naltrexone
22 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism Completed NCT00246441 Phase 4 Paroxetine;Placebo
23 A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room Completed NCT00457366 Phase 4 Quetiapine;Cocktail (Haloperidol, Lorazepam, Cogentin)
24 Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian Ethnicity Completed NCT00957866 Phase 4 Pegylated Interferons (Peg-IFN) and Ribavirin
25 The Effects of a Parental Intervention on Electronic Media Exposure and Sleep Patterns in Adolescents Completed NCT02365025 Phase 4
26 Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
27 Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder Completed NCT00156715 Phase 4 Quetiapine
28 Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder Completed NCT00130923 Phase 4 Risperidone Long Acting;oral risperidone
29 Drug Treatment for Depressed Alcoholics (Naltrexone/Fluoxetine) Completed NCT00006204 Phase 4 naltrexone (Revia);fluoxetine (Prozac)
30 Naltrexone, Craving, and Drinking Completed NCT00006203 Phase 4 naltrexone (Revia)
31 Naltrexone Treatment of Alcohol Dependence Completed NCT00000452 Phase 4 naltrexone (Revia)
32 Behavior and Naltrexone Treatment for Alcoholics Completed NCT00000449 Phase 4 naltrexone (Revia)
33 Use of Naltrexone in a Clinical Setting Completed NCT00000445 Phase 4 naltrexone (Revia)
34 Drug Therapy for Alcohol Detoxification Completed NCT00000441 Phase 4 lorazepam (Ativan);carbamazepine (Tegretol)
35 Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder Completed NCT00572117 Phase 4 Topiramate
36 Topiramate Treatment of Problem Drinkers Completed NCT00626925 Phase 4 topiramate;placebo
37 Biomarker Study of Acamprosate in Schizophrenia Completed NCT00688324 Phase 4 Acamprosate
38 The Whole Day First Grade Program Completed NCT00257088 Phase 4
39 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Completed NCT01015586 Phase 4 Lamotrigine;Placebo
40 Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism Completed NCT00920829 Phase 4 Naltrexone 50 Mg;Placebo
41 Pharmacogenetic Response to Naltrexone For Alcohol Dependence Completed NCT00831272 Phase 4 naltrexone;Placebo
42 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder Completed NCT00721526 Phase 4 disulfiram plus lorazepam
43 Naltrexone for Heavy Drinking in Young Adults Completed NCT00568958 Phase 4 naltrexone;placebo naltrexone
44 Targeted Naltrexone for Problem Drinkers Completed NCT00369408 Phase 4 Naltrexone;placebo
45 Sertraline Pharmacotherapy for Alcoholism Subtypes Completed NCT00368550 Phase 4 Sertraline;Placebo
46 The Effects of Topiramate on Alcohol Use in Alcohol Dependent Subjects Completed NCT00329407 Phase 4 Topiramate (Topamax)
47 Treatment of Alcohol Withdrawal in Hospital Patients Completed NCT00249366 Phase 4 Lorazepam (drug);Lorazepam
48 Combination Nicotine Replacement for Alcoholic Smokers Completed NCT00064844 Phase 4
49 Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone) Completed NCT00006489 Phase 4 Naltrexone;Placebo
50 Post-Treatment Effects of Naltrexone Completed NCT00006449 Phase 4 naltrexone (Revia)

Search NIH Clinical Center for Alcohol Abuse

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: alcoholism

Genetic Tests for Alcohol Abuse

Anatomical Context for Alcohol Abuse

MalaCards organs/tissues related to Alcohol Abuse:

41
Brain, Testes, Liver, Heart, Bone, Lung, Kidney

Publications for Alcohol Abuse

Articles related to Alcohol Abuse:

(show top 50) (show all 1839)
# Title Authors Year
1
The relationship between alcohol abuse and suicide risk according to smoking status: A cross-sectional study. ( 30342376 )
2019
2
Key personality traits and alcohol use disorder symptoms in first and second year college students: detangling antecedent from consequence. ( 30316144 )
2019
3
Investment in drinking identity is associated with alcohol consumption and risk of alcohol use disorder. ( 30368029 )
2019
4
The Effects of Cognitive-Behavioral Model-Based Intervention on Depression, Anxiety, and Self-Efficacy in Alcohol Use Disorder. ( 28778134 )
2019
5
Genome wide analysis of rare copy number variations in alcohol abuse or dependence. ( 29890507 )
2018
6
Effect of Chronic Alcohol Abuse on Anabolic and Catabolic Signaling Pathways in Human Skeletal Muscle. ( 29044624 )
2018
7
Cognitive impairment associated with cocaine use: The role of co-existent alcohol abuse/dependence. ( 29886366 )
2018
8
The Alcohol-Abuse Drug Disulfiram Targets NPL4 to Exert Antitumor Effects. ( 29247017 )
2018
9
Do general practitioners record alcohol abuse in the electronic medical records? A comparison of survey and medical record data. ( 29301406 )
2018
10
Valentin Magnan and Sergey Korsakov: French and Russian pioneers in the study of alcohol abuse. ( 29469655 )
2018
11
Hypokalemia associated with pseudo-Cushing's syndrome and magnesium deficiency induced by chronic alcohol abuse. ( 29450857 )
2018
12
Alcohol abuse numbers in Spain: nearly 420,000 deaths in current century. ( 29859629 )
2018
13
Everyday memory problems in alcohol abuse and dependence: Frequency, patterns and patient-proxy agreement. ( 29360054 )
2018
14
Effects of Alcohol Abuse on Proliferating Cells, Stem/Progenitor Cells, and Immature Neurons in the Adult Human Hippocampus. ( 29052615 )
2018
15
Single Nucleotide Polymorphisms in the Vitamin D Receptor Gene (<i>VDR</i>) May Have an Impact on Acute Pancreatitis (AP) Development: A Prospective Study in Populations of AP Patients and Alcohol-Abuse Controls. ( 29966312 )
2018
16
Hip osteonecroses treated with calcium sulfate-calcium phosphate bone graft substitute have different results according to the cause of osteonecrosis: alcohol abuse or corticosteroid-induced. ( 29550914 )
2018
17
Identifying adolescents with alcohol use disorder: Optimal screening using the National Institute on Alcohol Abuse and Alcoholism screening guide. ( 29975071 )
2018
18
Cancer: Anticancer effects of alcohol abuse drug. ( 29386611 )
2018
19
Development and validation of a Partial Least Squares-Discriminant Analysis (PLS-DA) model based on the determination of ethyl glucuronide (EtG) and fatty acid ethyl esters (FAEEs) in hair for the diagnosis of chronic alcohol abuse. ( 29174052 )
2018
20
Symptoms of alcohol abuse: The first warning sign of cancer development risk. ( 29983226 )
2018
21
Exploring Structural, Sociocultural, and Individual Barriers to Alcohol Abuse Treatment Among Hispanic Men. ( 30051746 )
2018
22
DNA methylation signatures: Biomarkers of drug and alcohol abuse. ( 30115428 )
2018
23
Clock genes polymorphisms in male bipolar patients with comorbid alcohol abuse. ( 30121446 )
2018
24
Nausea and vomiting · sensitivity to smell · history of hypertension and alcohol abuse · Dx? ( 30423000 )
2018
25
Phosphoinositide-specific phospholipase C in normal human liver and in alcohol abuse. ( 30426534 )
2018
26
The effect of the severity of parental alcohol abuse on mental and behavioural disorders in children. ( 30430262 )
2018
27
Alcohol abuse in road traffic: medical-legal aspects. ( 30441977 )
2018
28
CBI-20: Psychometric Properties for the Coping Behaviors Inventory for Alcohol Abuse in Brazil. ( 30483165 )
2018
29
Could Alcohol Abuse Drive Intimate Partner Violence Perpetrators' Psychophysiological Response to Acute Stress? ( 30513964 )
2018
30
The Effect of Donor Alcohol Abuse on Outcomes Following Heart Transplantation. ( 30536743 )
2018
31
Heterogeneous Dose-Response Analyses of Alcohol Abuse and Dependence. ( 30556903 )
2018
32
Relationship Between Attachment Style in Adulthood, Alexithymia, and Dissociation in Alcohol Use Disorder Inpatients. Mediational Model. ( 30425669 )
2018
33
Hyponatremia Associated With Tramadol in a Patient With Alcohol Use Disorder and Anxiety Taking Desvenlafaxine. ( 30550646 )
2018
34
Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder. ( 30325732 )
2018
35
Comorbid social anxiety disorder in patients with alcohol use disorder: A systematic review. ( 30236640 )
2018
36
Serial Progression from Attention-Deficit/Hyperactivity Disorder to Alcohol Use Disorder: Serial Multiple Mediated Effects of Externalizing Disorders and Depression. ( 30121976 )
2018
37
Serotonin receptors and suicide, major depression, alcohol use disorder and reported early life adversity. ( 30552318 )
2018
38
Heterogeneity of treatment dropout: PTSD, depression, and alcohol use disorder reductions in PTSD and AUD/SUD treatment noncompleters. ( 30419153 )
2018
39
Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV. ( 30469100 )
2018
40
S100B and Inflammatory Cytokine Levels in Blood as Potential Markers of Blood-Brain Barrier Damage and Psychiatric Impairment in Comorbid Hepatitis C Viral Infection and Alcohol Use Disorder. ( 29953169 )
2018
41
Alcohol use disorder tied to development of chronic kidney disease: A nationwide database analysis. ( 30188943 )
2018
42
Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence. ( 30327620 )
2018
43
Diagnosis and treatment of alcohol use disorder in patients with end-stage alcoholic liver disease. ( 30471136 )
2018
44
N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research. ( 30019966 )
2018
45
Lifetime alcohol intake and pattern of alcohol consumption in patients with alcohol-induced pancreatitis in comparison with patients with alcohol use disorder. ( 29595342 )
2018
46
Plasma levels of leptin in patients with pathological gambling, internet gaming disorder and alcohol use disorder. ( 30041134 )
2018
47
Genetically Informative Mediation Modeling Applied to Stressors and Personality-Disorder Traits in Etiology of Alcohol Use Disorder. ( 30536213 )
2018
48
Prediction of alcohol use disorder using personality disorder traits: a twin study. ( 28734091 )
2018
49
Personality disorder and treatment outcome in alcohol use disorder. ( 29059106 )
2018
50
Personality Disorder and Alcohol Use Disorder: An Overview. ( 29466805 )
2018

Variations for Alcohol Abuse

Expression for Alcohol Abuse

LifeMap Discovery
Genes differentially expressed in tissues of Alcohol Abuse patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 ADAMTS18 ADAM metallopeptidase with thrombospondin type 1 motif, 18 Brain - 3.66 0.005
Search GEO for disease gene expression data for Alcohol Abuse.

Pathways for Alcohol Abuse

Pathways related to Alcohol Abuse according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.53 BDNF DRD1 DRD2 DRD3 DRD4
2
Show member pathways
12.34 CNR1 DRD1 FAAH GABRA2
3 12.06 DRD1 DRD2 DRD3 DRD4
4
Show member pathways
11.87 AKR1A1 ALDH2 ALDH9A1 CYP2E1
5
Show member pathways
11.75 BDNF DRD1 DRD2
6 11.68 CNR1 DRD3 DRD4
7
Show member pathways
11.66 DRD2 DRD3 DRD4
8
Show member pathways
11.52 DRD1 DRD2 DRD3 DRD4
10 11.33 AKR1A1 ALDH2 ALDH9A1
11 11.09 BDNF DRD1 DRD2
12
Show member pathways
10.63 ALDH2 CYP2E1
13 10.47 DRD1 DRD2 DRD3

GO Terms for Alcohol Abuse

Cellular components related to Alcohol Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.76 CNR1 DRD1 DRD2 DRD3 DRD4 GABRA2
2 glutamatergic synapse GO:0098978 9.65 CNR1 DRD1 DRD2 DRD3 DRD4
3 endomembrane system GO:0012505 9.61 DRD1 FAAH SLC6A4
4 endocytic vesicle GO:0030139 9.54 DRD2 DRD3 TF
5 integral component of postsynaptic membrane GO:0099055 9.5 DRD1 DRD2 SLC6A4
6 dopaminergic synapse GO:0098691 9.4 DRD2 DRD3
7 GABA-ergic synapse GO:0098982 9.26 CNR1 DRD1 DRD2 DRD3
8 integral component of presynaptic membrane GO:0099056 8.92 CNR1 DRD1 DRD2 SLC6A4

Biological processes related to Alcohol Abuse according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.95